News
Health tech partnership to advance patient recruitment diversity and expand access to clinical trials
CardieX and Power are hoping to shift the paradigm on clinical trial diversity

The US health tech company CardieX has announced a partnership between its ATCOR subsidiary and the patient recruitment marketplace Power to “democratise” access to clinical trials.
The new partnership is hoped to allow ATCOR and Power to conduct collaborative research and advance underrepresented patient access to clinical trials and clinical research within women’s health, Alzheimer’s disease, diabetes, and cardiovascular disease.
The two companies aim to shift the paradigm on clinical trial diversity and change the current patient recruitment process.
A primary goal of the collaboration is the introduction of new approaches for screening patients with novel inclusion/exclusion criteria across all clinical trial models to increase patient access and patient diversity.
According to the developers, the “Pulse”, a new medical device from a CardieX subsidiary, will provide arterial health metrics to users from home, enabling any patient anywhere to be part of clinical trials.
Through the use of digital vascular biomarkers in the protocol, the device will enable customised patient recruitment to “enhance” diversity across populations.
Additionally, Power says its recruitment platform will make clinical trials accessible and inclusive of today’s socio-economic, geographic, and ethnicity disparities, enabling patient choice.
Toni R. Hofhine, president of CardieX subsidiary ATCOR Medical, said: “I am excited to partner with Power to advance patient recruitment diversity.
“Our ATCOR and Power partnership brings forward tremendous opportunity to push the boundaries of diversity within clinical trials.
“We will open doors for patients ‘anywhere’ to have equal access to clinical research and use our digital vascular biomarkers to enhance inclusion/exclusion criteria.”
Craig Cooper, group CEO of the CardieX companies, added: “Advancing underrepresented populations is essential for improving patient reported outcomes.
“The ATCOR and Power partnership will expand patient diversity across all clinical trial models, and I am excited to see the combined technologies engage the patient across some of the most challenging areas in medical research.”
Brandon Li, Power co-founder, said increasing patient access is key to improving representation in clinical research.
“Unfortunately, we don’t adequately understand the structural barriers that are often unintentionally exclusionary to people of colour,” he explained.
“I am excited to see our partnership with ATCOR begin to break down some of these barriers.”
The Pulse device will be available for healthcare research and clinical trials in the coming months.
Diagnosis
AI may help accelerate breast cancer diagnosis for high-risk women – study
Fertility
Infertility may be risk factor for early menopause, study suggests
News
Endometriosis documentary profiles stars including Marilyn Monroe and Amy Schumer

A non-profit has launched an endometriosis documentary featuring Amy Schumer and Marilyn Monroe as it pushes for changes in how the condition is treated and understood.
The Endometriosis Collective has launched to change how endometriosis is researched, treated and understood, starting with a documentary featuring stories from people including Amy Schumer and Marilyn Monroe.
The feature-length documentary, “End of the Cycle”, will premiere in New York on Tuesday, and The Endometriosis Collective is making the film free to stream online.
Schumer, a comedian, writer and actor, has previously spoken of how endometriosis left her “on the floor in pain, vomiting from the pain, the pain that nobody can see.”
Schumer is one of several celebrities featured in the documentary. Other contributors include dancer Julianne Hough, Olympic medallist Brittany Brown and actors Janel Parrish and Folake Olowofoyeku.
The Endometriosis Collective timed the documentary premiere to coincide with the 100th anniversary of Marilyn Monroe’s birth.
Monroe, who died in 1962, starred in films such as “Some Like It Hot” and “Gentlemen Prefer Blondes.”
According to a biography published in 1985, Monroe’s endometriosis was so severe that it destroyed her marriages, her wish for children, her career and ultimately her life.
The Endometriosis Collective said the documentary shares newly uncovered information about Monroe’s experience with endometriosis.
The non-profit said the information connects Monroe’s story to the experiences of women across generations, highlighting how far awareness, research and care still have to go.
A representative of the Marilyn Monroe Estate said: “By sharing this part of her story through ‘End of the Cycle,’ we hope to honour her legacy in a way that brings visibility to endometriosis, encourages more open dialogue and helps inspire the research needed to create change.”
As part of the premiere, The Endometriosis Collective is holding a panel discussion.
Schumer, Brown and Olowofoyeku, the documentary’s co-directors Sammy Jaye and Soraya Simi, and medical experts are due to be part of the premiere.
AbbVie’s Orilissa and Sumitomo Pharma’s Myfembree are among the approved drugs for endometriosis pain.
Hough, one of the participants in the documentary, starred in an Orilissa campaign in 2017.
Menopause1 week agoPerimenopause misinformation ‘putting women at risk’
News4 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Adolescent health4 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Insight3 weeks agoPCOS renamed after decade-long campaign to end ‘cyst’ misconception
Diagnosis2 weeks agoNHS urged to update website following renaming of PCOS
Mental health4 weeks agoCBT shows promise for menopause insomnia and hot flashes
Events4 weeks agoWHIS 2026 unveils agenda and first speakers for the leading women’s health summit
News7 days agoThree menopause innovators shortlisted for Femtech World Award















3 Comments